Clinical trials
Refractory Plasma Cell Myeloma clinical trials
Below are recruiting refractory plasma cell myeloma clinical trials, each written for real people, not researchers. We’re tracking 108 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05847569RecruitingPhase 2
Testing alternating doses of belantamab for hard-to-treat myeloma
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
Jacksonville, FloridaAges 18 years+ - NCT05312255Recruiting
Non-drug help to improve quality of life in myeloma
This study tests non-chemotherapy supports meant to improve quality of life and immune health for people with multiple myeloma (or related conditions). Depending on the group, it may involve activities, nutrition, and/or a medication like a beta blocker.
Buffalo, New YorkAges 18 years+ - NCT04879043RecruitingPhase 1/Phase 2
Safety study of HDP-101 for relapsed myeloma patients
This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.
Atlanta, GeorgiaAges 18 years+ - NCT04643002RecruitingPhase 1/Phase 2
Isatuximab added to other drugs for relapsed myeloma
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT04508790RecruitingPhase 2
Leflunomide plus pomalidomide with dexamethasone for relapsed myeloma
This trial studies whether a combination of three medicines (leflunomide, pomalidomide, and dexamethasone) can better treat multiple myeloma that has come back or stopped responding. It may help people who are not good candidates for transplant and who have measurable disease.
Duarte, CaliforniaAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT06948084RecruitingPhase 2
New drug combo vs usual care for high-risk multiple myeloma
This trial tests whether a new combination of drugs (daratumumab and teclistamab) works better than the usual treatments for multiple myeloma that has come back or stopped responding, especially in people with a high-risk form of the disease. Participants will be randomly assigned to get either the new combo or one of the standard combos.
Coeur d'Alene, IdahoAges 18 years+ - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+ - NCT06627751RecruitingPhase 2
Mezigdomide, Carfilzomib, and Dexamethasone for Relapsed Myeloma
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
Buffalo, New YorkAges 18 years+ - NCT07637578RecruitingPhase 2
Elranatamab infusions for relapsed or refractory myeloma
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
Denver, ColoradoAges 18 years+ - NCT05521802RecruitingPhase 1/Phase 2
Testing a new CAR-T therapy for relapsed myeloma
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
TianjinAges 18 years+ - NCT06645678RecruitingPhase 1/Phase 2
Mezigdomide and Elranatamab for relapsed or hard-to-treat multiple myeloma
This trial tests two drugs, mezigdomide (a pill) and elranatamab (an injection), in people whose multiple myeloma has come back or not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
SingaporeAges 19 years+ - NCT07181941RecruitingPhase 1/Phase 2
Testing lower doses of linvoseltamab for multiple myeloma
This trial tests if a lower dose of linvoseltamab can still work well for people with multiple myeloma that has come back or not responded to treatment. It aims to reduce side effects while keeping the cancer under control.
Seattle, WashingtonAges 18 years+ - NCT07681596RecruitingPhase 1/Phase 2
Study of a new drug for relapsed or refractory multiple myeloma
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Duarte, CaliforniaAges 18 years+ - NCT07579234RecruitingPhase 3
New drug F182112 for hard-to-treat multiple myeloma
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
TianjingAges 18 years+ - NCT07312188RecruitingPhase 2
F182112 for relapsed or refractory multiple myeloma
This trial tests a new drug, F182112, for people whose multiple myeloma came back or didn't respond to prior treatments that included lenalidomide and a proteasome inhibitor. It may help if your disease has active signs like high protein levels.
TianjinAges 18 years+ - NCT06484829RecruitingPhase 1/Phase 2
New drug combo for relapsed or refractory multiple myeloma
This trial tests a new drug, purinostat mesylate, combined with pomalidomide (a chemotherapy pill) and a low-dose steroid (dexamethasone) for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if this combination can help control the cancer with manageable side effects.
Chengdu, SichuanAges 18–75 - NCT07138209RecruitingPhase 3
Comparing QLS32015 to standard treatments for multiple myeloma
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07116616RecruitingPhase 1/Phase 2
mRNA vaccine for relapsed or refractory multiple myeloma
This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.
Birmingham, AlabamaAges 18 years+ - NCT06832865RecruitingPhase 2
Combination immunotherapy for relapsed multiple myeloma
This trial tests two drugs, elranatamab and isatuximab, given together to people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if the combination can shrink or control the cancer where other therapies have not worked well.
Boston, MassachusettsAges 18 years+ - NCT05565807RecruitingPhase 1/Phase 2
Study drug for difficult myeloma after prior treatments
This trial tests an anti-CD38 antibody drug that is “linked” to a cancer-killing payload (an antibody-drug conjugate) in people with multiple myeloma that has returned or did not respond to standard treatments. It is mainly looking at safety first, and also whether it can reduce myeloma in heavily pre-treated patients.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06574568RecruitingPhase 1
Study of YKST02 for relapsed or refractory multiple myeloma
This study tests a new drug called YKST02 for people with multiple myeloma that has come back or hasn't responded to other treatments. The goal is to see if it can help when other therapies have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06153251RecruitingPhase 1
Study of BMS-986453 for Relapsed or Refractory Multiple Myeloma
This study tests a new drug, BMS-986453, for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if it is safe and works against the cancer.
Birmingham, AlabamaAges 18 years+
Hear when a new Refractory Plasma Cell Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory plasma cell myeloma?
- Yes. Clin2 currently lists 108 recruiting refractory plasma cell myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory plasma cell myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory plasma cell myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.